FDA warns of allergy risk with antipsychotic Saphris (asenapine)
LOS ANGELES (Reuters) - The U.S. Food and Drug Administration warned on Thursday that serious allergic reactions have been reported with the use of Merck amp; Co Inc's atypical antipsychotic drug Saphris (asenapine). (Source: Modern Medicine)

Schering-Plough Submits Response to FDA for Saphris (asenapine) in the Acute Treatment of Both Schizophrenia and Bipolar I Disorder
Response submitted within one month of FDA complete response letter KENILWORTH, N.J., February 20, 2009 /PRNewswire-FirstCall/ -- Schering-Plough Corporation today announced that it has responded to the U.S. Food and Drug Administration (FDA)... (Source: Drugs.com - New Drug Applications)